SPACEGEN

Xiamen SpacegenCo., Ltd.,
Specializing in the development, manufacture and marketing of diagnostic tests for targeted therapies in oncology. Spacegen’s patented diagnostic technology makes early targeted screening, drug selection and efficacy monitoring efficient and are cost-effective.

Spacegen has 3500 ㎡GMP production areas,2000㎡ R&D/QC laboratories and1500 ㎡ office areas.
Subsidiary Laboratory includes Xiamen SpaceSeq MedLab Co., Ltd and Suzhou SpaceSeq MedLab Co., Ltd which has medical institution practice license and is in accordance with the P2+ standard.

Spacegen® has developed patent technologies including RingCap® (Ring-Link Capture Library technology) and PAP-ARMS (pyrophosphorolysis-activated polymerization amplification refractory mutation system)

RingCap® advantages:

(1) Ease of Use: Based on the independent patent technology RingCap®, Library preparation in 2 steps..;

(2)Fast Results： The library preparation takes only 3.5 hours, 2 working days from sampling to reporting.

(3) High Sensitivity and Comprehensive Coverage.

(4)Multiple Instruments: Reagents are compatible with Illumina® NextSeq 500, MiniSeq, and MiSeq and Ion Torrent PGMS5,Proton sequencers.

PAP-ARMS Technical advantages:

(1). Accuracy and Reliability:Use sub-packed PCR tube to effectively avoid cross-contamination.

(2)High Sensitivity and Comprehensive Coverage.

(3)Great versatility: Validated on the most common qPCR machines with stable results.

Spacegen® focus on Genomic and Molecular Oncology.

SpaceGen adheres o the mission of "benefiting the health of the public" and aims to be a leading international specialized molecular diagnostic company. We value Top quality， excellent reputation， rigorous management and superior service " ，we strive to move forward with good results to reward society and benefit patients!